110 related articles for article (PubMed ID: 33103598)
1. Antagonistic interaction between TTA-A2 and paclitaxel for anti-cancer effects by complex formation with T-type calcium channel.
Kumari N; Dalal V; Kumar P; Rath SN
J Biomol Struct Dyn; 2022 Apr; 40(6):2395-2406. PubMed ID: 33103598
[TBL] [Abstract][Full Text] [Related]
2. T-type calcium channel antagonist, TTA-A2 exhibits anti-cancer properties in 3D spheroids of A549, a lung adenocarcinoma cell line.
Kumari N; Bhargava A; Rath SN
Life Sci; 2020 Nov; 260():118291. PubMed ID: 32810510
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant role of a T-type calcium channel blocker, TTA-A2, in lung cancer treatment with paclitaxel.
Kumari N; Giri PS; Rath SN
Cancer Drug Resist; 2021; 4(4):996-1007. PubMed ID: 35582374
[No Abstract] [Full Text] [Related]
4. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice.
Kraus RL; Li Y; Gregan Y; Gotter AL; Uebele VN; Fox SV; Doran SM; Barrow JC; Yang ZQ; Reger TS; Koblan KS; Renger JJ
J Pharmacol Exp Ther; 2010 Nov; 335(2):409-17. PubMed ID: 20682849
[TBL] [Abstract][Full Text] [Related]
5. Blockade of T-type calcium channels prevents tonic-clonic seizures in a maximal electroshock seizure model.
Sakkaki S; Gangarossa G; Lerat B; Françon D; Forichon L; Chemin J; Valjent E; Lerner-Natoli M; Lory P
Neuropharmacology; 2016 Feb; 101():320-9. PubMed ID: 26456350
[TBL] [Abstract][Full Text] [Related]
6. Cross-modulation and molecular interaction at the Cav3.3 protein between the endogenous lipids and the T-type calcium channel antagonist TTA-A2.
Cazade M; Nuss CE; Bidaud I; Renger JJ; Uebele VN; Lory P; Chemin J
Mol Pharmacol; 2014 Feb; 85(2):218-25. PubMed ID: 24214826
[TBL] [Abstract][Full Text] [Related]
7. State-dependent properties of a new T-type calcium channel blocker enhance Ca(V)3.2 selectivity and support analgesic effects.
Francois A; Kerckhove N; Meleine M; Alloui A; Barrere C; Gelot A; Uebele VN; Renger JJ; Eschalier A; Ardid D; Bourinet E
Pain; 2013 Feb; 154(2):283-293. PubMed ID: 23257507
[TBL] [Abstract][Full Text] [Related]
8. ZnT1 induces a crosstalk between T-type and L-type calcium channels through interactions with Raf-1 kinase and the calcium channel β2 subunit.
Mor M; Beharier O; Cook DI; Campbell CR; Gheber LA; Katz A; Moran A; Etzion Y
Metallomics; 2023 Jun; 15(6):. PubMed ID: 37193665
[TBL] [Abstract][Full Text] [Related]
9. T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats.
Uslaner JM; Smith SM; Huszar SL; Pachmerhiwala R; Hinchliffe RM; Vardigan JD; Nguyen SJ; Surles NO; Yao L; Barrow JC; Uebele VN; Renger JJ; Clark J; Hutson PH
Neuropharmacology; 2012 Mar; 62(3):1413-21. PubMed ID: 21110986
[TBL] [Abstract][Full Text] [Related]
10. Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter.
Zhang Q; Song Y; Cheng X; Xu Z; Matthew OA; Wang J; Sun Z; Zhang X
Anticancer Res; 2019 Oct; 39(10):5461-5471. PubMed ID: 31570440
[TBL] [Abstract][Full Text] [Related]
11. Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Kumfu S; Chattipakorn SC; Fucharoen S; Chattipakorn N
Exp Physiol; 2016 Apr; 101(4):521-39. PubMed ID: 26824522
[TBL] [Abstract][Full Text] [Related]
12. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAF
Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet X; Matías-Guiu X; Martí RM; Macià A
J Invest Dermatol; 2020 Jun; 140(6):1253-1265. PubMed ID: 31877318
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel-induced apoptosis is blocked by camptothecin in human breast and pancreatic cancer cells.
Jeansonne DP; Koh GY; Zhang F; Kirk-Ballard H; Wolff L; Liu D; Eilertsen K; Liu Z
Oncol Rep; 2011 May; 25(5):1473-80. PubMed ID: 21331447
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Combination of Sodium Aescinate-Stabilized, Polymer-Free, Twin-Like Nanoparticles to Reverse Paclitaxel Resistance.
Li J; Zheng L; Wang R; Sun D; Liang S; Wu J; Liu Y; Tian X; Li T; Yang Y; Han L
Int J Nanomedicine; 2020; 15():5839-5853. PubMed ID: 32848393
[TBL] [Abstract][Full Text] [Related]
15. CaV3.2 T-type Ca2+ channels mediate the augmented calcium influx in carotid body glomus cells by chronic intermittent hypoxia.
Makarenko VV; Ahmmed GU; Peng YJ; Khan SA; Nanduri J; Kumar GK; Fox AP; Prabhakar NR
J Neurophysiol; 2016 Jan; 115(1):345-54. PubMed ID: 26561606
[TBL] [Abstract][Full Text] [Related]
16. JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo.
Wang C; Wang R; Zhou K; Wang S; Wang J; Shi H; Dou Y; Yang D; Chang L; Shi X; Liu Y; Xu X; Zhang X; Ke Y; Liu H
Cancer Chemother Pharmacol; 2016 Nov; 78(5):971-982. PubMed ID: 27620208
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
18. Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth.
Yang X; Zhao D; Li Y; Li Y; Cui W; Li Y; Li H; Li X; Wang D
Thorac Cancer; 2020 Oct; 11(10):2858-2866. PubMed ID: 32875729
[TBL] [Abstract][Full Text] [Related]
19. Synergistic anticancer effects of andrographolide and paclitaxel against A549 NSCLC cells.
Yuan H; Sun B; Gao F; Lan M
Pharm Biol; 2016 Nov; 54(11):2629-2635. PubMed ID: 27159496
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-22 enhances chemoresistance of lung adenocarcinoma cells to paclitaxel.
Huang Z; Gao Y; Hou D
Hum Cell; 2020 Jul; 33(3):850-858. PubMed ID: 32452013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
